PharmaShots

US WorldMeds Acquires Orbus Therapeutics to Advance Eflornithine in Adult Malignant Glioma

Oct 28, 2026, 11:49 AM

Translate article text

Choose a language and wait for the translated text.

Shots: US WorldMeds has acquired Orbus Therapeutics, adding its late-stage oral eflornithine (DFMO) program for recurrent Grade 3 astrocytoma; Orbus is now a wholly owned subsidiary of US WorldMeds US WorldMeds made an undisclosed upfront payment, with Orbus eligible for development, regulatory & sales milestones, plus tiered royalties on US net sales The P-III (STELLAR) trial (n=343) of eflornithine + lomustine vs lomustine missed its OS 1EP in the ITT population; in the prespecified IDH-mutant Grade 3 astrocytoma subset (n=196), mOS was 34.9 vs 23.5mos. (HR=0.64) & mPFS 15.8 vs 7.2mos. (HR=0.57) Ref: PR Newswire  |   Image: US WorldMeds  |  Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post US WorldMeds Acquires Orbus Therapeutics to Advance Eflornithine in Adult Malignant Glioma appeared first on PharmaShots.